|Publication number||US9592254 B2|
|Application number||US 14/162,915|
|Publication date||14 Mar 2017|
|Filing date||24 Jan 2014|
|Priority date||6 Feb 2013|
|Also published as||CA2899724A1, CN104994893A, EP2953658A1, US20140220095, US20170209619, WO2014123703A1|
|Publication number||14162915, 162915, US 9592254 B2, US 9592254B2, US-B2-9592254, US9592254 B2, US9592254B2|
|Inventors||Gary Monteiro, Christopher T. Wagner, Neil L. Rodriguez, Aubrey Irene Delossantos|
|Original Assignee||Lifecell Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (104), Non-Patent Citations (46), Classifications (5), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application 61/761,298, which was filed on Feb. 6, 2013, and which is incorporated by reference in its entirety.
The present disclosure relates to tissue matrices, and more particularly, to methods for localized modification of mechanical and/or biological properties of tissue matrices.
Various tissue-derived products are used to regenerate, repair, or otherwise treat diseased or damaged tissues and organs. Such products can include intact tissue grafts and/or acellular or reconstituted acellular tissues (e.g., acellular tissue matrices from skin, intestine, or other tissues, with or without cell seeding). Such products generally have mechanical properties determined by the tissue source (i.e., tissue type and animal from which it originated) and the processing parameters used to produce the tissue products. Since tissue products are often used for surgical applications and/or tissue replacement or augmentation, the mechanical and biological properties of the tissue products are important. For example, tissue products must be able to provide suitable mechanical support (e.g., to close a tissue defect), while allowing tissue in-growth and regeneration. In some cases, however, it may be desirable to modify the mechanical and/or biological properties of tissue products. Furthermore, in order to improve the performance of tissue products for specific applications, it may be desirable to produce tissue products that have variable mechanical and/or biological properties. Accordingly, the present disclosure provides devices and methods for localized modification of mechanical and/or biological properties of tissue products, including acellular tissue matrices.
According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
In some embodiments, the method comprises cross-linking select portions of the tissue matrix by applying a fluid containing a cross-linking agent to the select portions. In certain embodiments, applying a fluid containing a cross-linking agent to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethough; contacting the tissue matrix with the surface; and causing fluid containing a cross-linking agent to flow through the channels. In various embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern. In various embodiments, the cross-linking agent comprises at least one of gluteraldehyde, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), or genepin.
In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix. In some embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises applying a fluid containing the proteolytic enzyme to the select portions. In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises providing a solid surface having one or more channels configured to allow fluid to flow therethough; contacting the tissue matrix with the surface; and causing fluid containing the proteolytic enzyme to flow through the channels. In some embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern and a linear pattern.
In certain embodiments, the enzyme is bromelain. In some embodiments, the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.
In some embodiments, the method further includes treating the tissue matrix to removal at least some of the cells and cellular components from the tissue matrix. In some embodiments, the method includes removing all the cells and cellular components from the tissue matrix.
In various embodiments, tissue products produced according to any of the disclosed methods are provided.
In certain embodiments, a tissue product is provided. The tissue product can comprise an acellular tissue matrix derived from a collagen-containing tissue, wherein the tissue matrix comprises a flexible sheet, and wherein the tissue matrix comprises select regions of cross-linked or proteolytically digested material, and wherein the mechanical or biological properties of the tissue matrix vary across the flexible sheet.
Reference will now be made in detail to certain exemplary embodiments according to the present disclosure, certain examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Any ranges described herein will be understood to include the endpoints and all values between the endpoints.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.
As used herein “tissue product” will refer to any human or animal tissue that contains extracellular matrix proteins. “Tissue products” can include acellular or partially decellularized tissue matrices, as well as decellularized tissue matrices that have been repopulated with exogenous cells.
Various human and animal tissues can be used to produce products for treating patients. For example, various tissue products are available for regeneration, repair, augmentation, reinforcement, and/or treatment of human tissues that have been damaged or lost due to various diseases and/or structural damage (e.g., from trauma, surgery, atrophy, and/or long-term wear and degeneration). Such products can include, for example, acellular tissue matrices, tissue allografts or xenografts, and/or reconstituted tissues (i.e., at least partially decellularized tissues that have been seeded with cells to produce viable materials).
For surgical applications, it is often desirable to produce tissue products that have certain mechanical properties. For example, the tissue product, which may include a sheet of material, should possess sufficient strength to withstand stresses during the intended use. Certain tissue products may be used to repair defects (e.g., hernias), to support surrounding tissues or implants (e.g., for breast augmentation and/or reconstruction), or to replace damaged or lost tissue (e.g., after trauma or surgical resection). Whatever the particular use, the tissue product should have sufficient strength, elasticity, and/or other mechanical properties to function until tissue regeneration and/or repair occurs.
Some tissue products, however, may be functionally improved by altering the mechanical properties of the products. For example, a number of acellular tissue matrix products are available, and often, such tissue matrices are in the form of a flexible sheet of material that has substantially uniform mechanical and/or biological properties over its entire surface area. For some indications, however, it may be desirable to alter the mechanical and/or biological properties of such tissue matrices such that the properties vary across the material. For example, in some embodiments, it may be desirable to strengthen, stiffen, weaken, or make more pliable select regions of a tissue product to produce a product having variable mechanical properties. In addition, in some embodiments, it may be desirable to modify certain elastic or viscoelastic properties of a tissue matrix, including, for example, the resistance to stretching at low deformation levels (e.g., toe-region mechanics).
It may be desirable to treat select regions of the tissue products to control the rate of degradation, cell in-growth, and/or vascularization after implantation. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.
The present disclosure provides methods for treating tissues to provide variable mechanical and/or biological properties along the length, width, or thickness of a tissue matrix. The disclosure also provides tissue products produced using the methods of treatments.
According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical and/or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix.
In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix.
The tissue products according to the present disclosure can be selected to provide a variety of different biological and/or mechanical properties. For example, an acellular tissue matrix or other tissue product can be selected to allow tissue in-growth and remodeling to assist in regeneration of tissue normally found at the site where the matrix is implanted. For example, an acellular tissue matrix, when implanted on or into fascia or other soft tissue, may be selected to allow regeneration of the fascia or other soft tissue without excessive fibrosis or scar formation. In certain embodiments, the tissue product can be formed from ALLODERM® or STRATTICE™ (LIFECELL CORPORATION, Branchburg, N.J.), which are human and porcine acellular dermal matrices respectively. Alternatively, other suitable acellular tissue matrices can be used, as described further below. The tissues can be selected from a variety of tissue sources including skin (dermis or whole skin), fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue. The methods described herein can be used to process any collagenous tissue type and for any tissue matrix product. For example, a number of biological scaffold materials are described by Badylak et al., and the methods of the present disclosure can be used to treat those or other tissue products known in the art. Badylak et al., “Extracellular Matrix as a Biological Scaffold Material: Structure and Function,” Acta Biomaterialia (2008), doi:10.1016/j.actbio.2008.09.013.
In some cases, the tissue matrix can be provided as a decellularized tissue matrix. Suitable acellular tissue matrices are described further below. In other cases, the method can further include processing intact tissue to remove cells or other materials either before, after, or both before and after cross-linking or proteolytic treatment according to the present application. The tissues can be completely or partially decellularized to yield acellular tissue matrices or extracellular tissue materials to be used for patients. For example, various tissues, such as skin, intestine, bone, cartilage, nerve tissue (e.g., nerve fibers or dura), tendons, ligaments, or other tissues can be completely or partially decellularized to produce tissue products useful for patients. In some cases, these decellularized products can be used without addition of exogenous cellular materials (e.g., stem cells). In certain cases, these decellularized products can be seeded with cells from autologous sources or other sources to facilitate treatment. Suitable processes for producing acellular tissue matrices are described below.
In certain embodiments, tissue matrices can be treated to provide localized variation in mechanical and/or biological properties by contacting the tissue matrices with one or more cross-linking agents and/or proteolytic enzymes. Generally, the matrices can be treated by contacting selected portions of the tissue matrices with a fluid containing the agent or enzyme and under conditions (e.g., temperature and/or pH) and for a time sufficient to produce a desired degree of cross-linking and/or proteolysis.
The fluid containing cross-linking agents or enzymes can be applied to selected regions of the tissue matrix in a variety of ways. In certain embodiments, the fluid is made to flow in contact with the tissue matrix to permit contact with only those regions of the tissue matrix that are selected for modification.
The channels 16 can have a variety of shapes, sizes and configurations. In general, the channels 16 should be spaced far enough apart to allow a seal to form between channels when placed in contact with a tissue matrix. Further, suitable channel widths can range from 1 micron to 5 cm, and suitable channel heights can range from 1 micron to 2 mm. In addition, the channel edges should be rounded or blunted to prevent tissue damage.
A number of different cross-linking agents and/or enzymes can be used to treat the tissue matrices. For example, suitable cross-linking agents can include gluturaldyhyde, EDC, genepin, aldehydes, and/or lysyl oxidase; and suitable enzymes can include sulfhydryl proteases such as bromelain. In addition, the enzymes can include bromelain, papain, ficin, actinidin, or combinations thereof. The enzymes and cross-linking agents can be purchased commercially; or enzymes can be extracted from fruit sources. For example, one source of bromelain is MCCORMICK MEAT TENDERIZER, but the enzymes can also be extracted from pineapple and/or purchased in a medical-grade formulation.
The enzymes can be contacted with the tissues to increase the pliability of the tissue without causing undesirable degradation in other mechanical and/or biological properties. For example, when a batch of materials is produced with or without the enzyme treatments discussed herein, the enzyme treatments will not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, collagenase susceptibility, glycosaminoglycan content, lectin content, burst strength, thermal transition temperature, or combinations thereof. In some cases, an undesirable change is a statistically significant reduction any one of tensile strength, tear strength, suture strength, creep resistance, glycosaminoglycan content, lectin content, burst strength; an increase in collagenase susceptibility; or a change (upward or downward) in thermal transition temperature (as measure using differential scanning calorimetry).
In some cases, the enzymes are selected such that they cause site-specific cleavage of proteins within the tissues. For example, it has been found that treatment of porcine dermal materials with bromelain does not cause further alterations in the matrix structure after a certain amount of treatment. Therefore, treatment of dermis with bromelain does not cause further change in the matrix with prolonged exposure or after extended periods of time.
In addition, the enzymes and cross-linking agents can be applied to the tissues in a variety of suitable solutions. For example, bromelain has been found to be effective when applied to tissues in normal saline, but other suitable buffers (e.g., PBS) can be used.
The device 10 used to contact the tissue matrix 19 with enzymes and/or cross-linking agents can have a variety of different configurations. For example, as described in further detail below with respect to
The methods of the present disclosure can be used to modify mechanical and/or biological properties in a number of different locations.
The specific pattern of the region selected for localized cross-linking or proteolytic treatment can be selected for a variety of reasons. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Excessive cross-linking, however, can have adverse effects on cell infiltration and regeneration of normal tissue within the tissue matrix. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.
Localized protease treatment may be used for a variety of reasons. For example, localized protease treatment can allow production of differing strength or other mechanical properties treating the tissue to make native stronger. In addition, production of tissue matrices with localized pliability may be to allow a surgeon to place tissue in small openings, including passing a tissue matrix through a laparoscopic incision or trocar. In addition, production of tissue with localized pliability can be beneficial to allow matching of compliances with natural tissues or to match anisotropic mechanical properties of tissues.
The specific pattern of localized treatment may be selected based on a desired implantation site or treatment method. For example, in various embodiments, the pattern may be selected to provide a treated tissue matrix having improved mechanical properties (e.g., higher yield strength) along dimensions that may be more likely to experience higher loads during use. For example, in the embodiments of
The concentration, flow-rate, and specific enzyme or chemical used for cross-linking or proteolysis can be selected for a variety of reasons. For example, in general, the specific concentration and flow rate/time of exposure is selected based on the desired degree of cross-linking or proteolysis. In addition, since different enzymes and/or cross-linking agents may have proteolytic or cross-linking effects on different amino acids, combinations of two or more enzymes or cross-linking agents can be used.
Acellular Tissue Matrices
The methods of the present disclosure can be used to provide localized modification of properties of any tissue matrix, including the tissue matrix of cellularized tissues, partially decellularized tissue, or artificially manufactured matrices. In some embodiments, however, the tissue matrices include acellular tissue matrice. The term “acellular tissue matrix,” as used herein, refers generally to any tissue matrix that is substantially free of cells and/or cellular components.
Tissue matrices can be processed in a variety of ways, as described below to produce decellularized or partially decellularized tissues. The processing steps described below can be used along with and of (either before or after) the processes described herein for producing tissue matrices having variations mechanical and/or biological properties.
In general, the steps involved in the production of an acellular tissue matrix include harvesting the tissue from a donor (e.g., a human cadaver or animal source) and cell removal under conditions that preserve biological and structural function. In certain embodiments, the process includes chemical treatment to stabilize the tissue and avoid biochemical and structural degradation together with or before cell removal. In various embodiments, the stabilizing solution arrests and prevents osmotic, hypoxic, autolytic, and proteolytic degradation, protects against microbial contamination, and reduces mechanical damage that can occur with tissues that contain, for example, smooth muscle components (e.g., blood vessels). The stabilizing solution may contain an appropriate buffer, one or more antioxidants, one or more oncotic agents, one or more antibiotics, one or more protease inhibitors, and/or one or more smooth muscle relaxants.
The tissue is then placed in a decellularization solution to remove viable cells (e.g., epithelial cells, endothelial cells, smooth muscle cells, and fibroblasts) from the structural matrix without damaging the biological and structural integrity of the collagen matrix. The decellularization solution may contain an appropriate buffer, salt, an antibiotic, one or more detergents (e.g., TRITON X-100™, sodium deoxycholate, polyoxyethylene (20) sorbitan mono-oleate), one or more agents to prevent cross-linking, one or more protease inhibitors, and/or one or more enzymes. In some embodiments, the decellularization solution comprises 1% TRITON X-100™ in RPMI media with Gentamicin and 25 mM EDTA (ethylenediaminetetraacetic acid). In some embodiments, the tissue is incubated in the decellularization solution overnight at 37° C. with gentle shaking at 90 rpm. In certain embodiments, additional detergents may be used to remove fat from the tissue sample. For example, in some embodiments, 2% sodium deoxycholate is added to the decellularization solution.
Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure. Acellular tissue matrices can be tested or evaluated to determine if they are substantially free of cell and/or cellular components in a number of ways. For example, processed tissues can be inspected with light microscopy to determine if cells (live or dead) and/or cellular components remain. In addition, certain assays can be used to identify the presence of cells or cellular components. For example, DNA or other nucleic acid assays can be used to quantify remaining nuclear materials within the tissue matrices. Generally, the absence of remaining DNA or other nucleic acids will be indicative of complete decellularization (i.e., removal of cells and/or cellular components). Finally, other assays that identify cell-specific components (e.g., surface antigens) can be used to determine if the tissue matrices are acellular. Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure.
After the decellularization process, the tissue sample is washed thoroughly with saline. In some exemplary embodiments, e.g., when xenogenic material is used, the decellularized tissue is then treated overnight at room temperature with a deoxyribonuclease (DNase) solution. In some embodiments, the tissue sample is treated with a DNase solution prepared in DNase buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 20 mM CaCl2 and 20 mM MgCl2). Optionally, an antibiotic solution (e.g., Gentamicin) may be added to the DNase solution. Any suitable buffer can be used as long as the buffer provides suitable DNase activity.
While an acellular tissue matrix may be made from one or more individuals of the same species as the recipient of the acellular tissue matrix graft, this is not necessarily the case. Thus, for example, an acellular tissue matrix may be made from porcine tissue and implanted in a human patient. Species that can serve as recipients of acellular tissue matrix and donors of tissues or organs for the production of the acellular tissue matrix include, without limitation, mammals, such as humans, nonhuman primates (e.g., monkeys, baboons, or chimpanzees), pigs, cows, horses, goats, sheep, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats, or mice.
Elimination of the α-gal epitopes from the collagen-containing material may diminish the immune response against the collagen-containing material. The α-gal epitope is expressed in non-primate mammals and in New World monkeys (monkeys of South America) as well as on macromolecules such as proteoglycans of the extracellular components. U. Galili et al., J. Biol. Chem. 263: 17755 (1988). This epitope is absent in Old World primates (monkeys of Asia and Africa and apes) and humans, however. Id. Anti-gal antibodies are produced in humans and primates as a result of an immune response to α-gal epitope carbohydrate structures on gastrointestinal bacteria. U. Galili et al., Infect. Immun. 56: 1730 (1988); R. M. Hamadeh et al., J. Clin. Invest. 89: 1223 (1992).
Since non-primate mammals (e.g., pigs) produce α-gal epitopes, xenotransplantation of collagen-containing material from these mammals into primates often results in rejection because of primate anti-Gal binding to these epitopes on the collagen-containing material. The binding results in the destruction of the collagen-containing material by complement fixation and by antibody dependent cell cytotoxicity. U. Galili et al., Immunology Today 14: 480 (1993); M. Sandrin et al., Proc. Natl. Acad. Sci. USA 90: 11391 (1993); H. Good et al., Transplant. Proc. 24: 559 (1992); B. H. Collins et al., J. Immunol. 154: 5500 (1995). Furthermore, xenotransplantation results in major activation of the immune system to produce increased amounts of high affinity anti-gal antibodies. Accordingly, in some embodiments, when animals that produce α-gal epitopes are used as the tissue source, the substantial elimination of α-gal epitopes from cells and from extracellular components of the collagen-containing material, and the prevention of re-expression of cellular α-gal epitopes can diminish the immune response against the collagen-containing material associated with anti-gal antibody binding to α-gal epitopes.
To remove α-gal epitopes, after washing the tissue thoroughly with saline to remove the DNase solution, the tissue sample may be subjected to one or more enzymatic treatments to remove certain immunogenic antigens, if present in the sample. In some embodiments, the tissue sample may be treated with an α-galactosidase enzyme to eliminate α-gal epitopes if present in the tissue. In some embodiments, the tissue sample is treated with α-galactosidase at a concentration of 300 U/L prepared in 100 mM phosphate buffer at pH 6.0. In other embodiments, the concentration of α-galactosidase is increased to 400 U/L for adequate removal of the α-gal epitopes from the harvested tissue. Any suitable enzyme concentration and buffer can be used as long as sufficient removal of antigens is achieved.
Alternatively, rather than treating the tissue with enzymes, animals that have been genetically modified to lack one or more antigenic epitopes may be selected as the tissue source. For example, animals (e.g., pigs) that have been genetically engineered to lack the terminal α-galactose moiety can be selected as the tissue source. For descriptions of appropriate animals see co-pending U.S. application Ser. No. 10/896,594 and U.S. Pat. No. 6,166,288, the disclosures of which are incorporated herein by reference in their entirety. In addition, certain exemplary methods of processing tissues to produce acellular matrices with or without reduced amounts of or lacking alpha-1,3-galactose moieties, are described in Xu, Hui. et al., “A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-α-(1,3)-Galactose and Retention of Matrix Structure,” Tissue Engineering, Vol. 15, 1-13 (2009), which is incorporated by reference in its entirety.
After the acellular tissue matrix is formed, histocompatible, viable cells may optionally be seeded in the acellular tissue matrix to produce a graft that may be further remodeled by the host. In some embodiments, histocompatible viable cells may be added to the matrices by standard in vitro cell co-culturing techniques prior to transplantation, or by in vivo repopulation following transplantation. In vivo repopulation can be by the recipient's own cells migrating into the acellular tissue matrix or by infusing or injecting cells obtained from the recipient or histocompatible cells from another donor into the acellular tissue matrix in situ. Various cell types can be used, including embryonic stem cells, adult stem cells (e.g. mesenchymal stem cells), and/or neuronal cells. In various embodiments, the cells can be directly applied to the inner portion of the acellular tissue matrix just before or after implantation. In certain embodiments, the cells can be placed within the acellular tissue matrix to be implanted, and cultured prior to implantation.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4582640||22 Oct 1984||15 Apr 1986||Collagen Corporation||Injectable cross-linked collagen implant material|
|US4902508||11 Jul 1988||20 Feb 1990||Purdue Research Foundation||Tissue graft composition|
|US4969912||18 Feb 1988||13 Nov 1990||Kelman Charles D||Human collagen processing and autoimplant use|
|US5104957||28 Feb 1990||14 Apr 1992||Autogenesis Technologies, Inc.||Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom|
|US5131850||3 Nov 1989||21 Jul 1992||Cryolife, Inc.||Method for cryopreserving musculoskeletal tissues|
|US5160313||14 May 1991||3 Nov 1992||Cryolife, Inc.||Process for preparing tissue for transplantation|
|US5231169||26 Feb 1992||27 Jul 1993||Norian Corporation||Mineralized collagen|
|US5254133||24 Apr 1991||19 Oct 1993||Seid Arnold S||Surgical implantation device and related method of use|
|US5275826||13 Nov 1992||4 Jan 1994||Purdue Research Foundation||Fluidized intestinal submucosa and its use as an injectable tissue graft|
|US5284655||4 Feb 1992||8 Feb 1994||Osteotech, Inc.||Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects|
|US5332802||11 Jun 1992||26 Jul 1994||Autogenesis Technologies, Inc.||Human collagen processing and autoimplant use|
|US5332804||16 Apr 1991||26 Jul 1994||Synergen, Inc.||High molecular weight human angiogenic basic fibroblast growth factors|
|US5336616||2 Feb 1993||9 Aug 1994||Lifecell Corporation||Method for processing and preserving collagen-based tissues for transplantation|
|US5364756||16 Feb 1993||15 Nov 1994||Lifecell||Method of cryopreserving a suspension of biological material|
|US5489304||19 Apr 1994||6 Feb 1996||Brigham & Women's Hospital||Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft|
|US5547681||14 Jul 1994||20 Aug 1996||Union Carbide Chemicals & Plastics Technology Corporation||Dermal patch|
|US5613982||5 Jun 1995||25 Mar 1997||Cryolife, Inc.||Method of preparing transplant tissue to reduce immunogenicity upon implantation|
|US5632778||5 Jun 1995||27 May 1997||Cryolife, Inc.||Treated tissue for implantation and methods of preparation|
|US5641518||10 Feb 1995||24 Jun 1997||Purdue Research Foundation||Method of repairing bone tissue|
|US5728752||15 Mar 1996||17 Mar 1998||Ethicon, Inc.||Injectable microdipersions for soft tissue repair and augmentation|
|US5739176||18 Mar 1994||14 Apr 1998||Atrix Laboratories, Inc.||Biodegradable in-situ forming implants and methods of producing the same|
|US5800537||6 Jun 1995||1 Sep 1998||Tissue Engineering, Inc.||Method and construct for producing graft tissue from an extracellular matrix|
|US5893888||6 Sep 1994||13 Apr 1999||Tissue Engineering, Inc.||Method and construct for producing graft tissue from extracellular matrix|
|US5993844||8 May 1997||30 Nov 1999||Organogenesis, Inc.||Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix|
|US6027743||2 Jun 1995||22 Feb 2000||Stryker Corporation||Manufacture of autogenous replacement body parts|
|US6096347||4 Nov 1997||1 Aug 2000||Purdue Research Foundation||Myocardial graft constructs|
|US6113623||31 Dec 1997||5 Sep 2000||Cabinet Beau De Lomenie||Prosthetic device and method for eventration repair|
|US6166288||3 Jul 1996||26 Dec 2000||Nextran Inc.||Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor|
|US6179872||17 Mar 1998||30 Jan 2001||Tissue Engineering||Biopolymer matt for use in tissue repair and reconstruction|
|US6194136||13 Jul 1998||27 Feb 2001||Lifecell Corporation||Cryoprotective solutions comprising DMSO, PG, 2,3-butanediol,raffinose and PVP|
|US6326018||7 Oct 1999||4 Dec 2001||Musculoskeletal Transplant Foundation||Flexible sheet of demineralized bone|
|US6371992||19 Dec 1997||16 Apr 2002||The Regents Of The University Of California||Acellular matrix grafts: preparation and use|
|US6381026||15 Mar 1999||30 Apr 2002||Lifecell Corp.||Method of measuring the contour of a biological surface|
|US6432710||3 Oct 2000||13 Aug 2002||Isolagen Technologies, Inc.||Compositions for regenerating tissue that has deteriorated, and methods for using such compositions|
|US6485723||8 May 2000||26 Nov 2002||Purdue Research Foundation||Enhanced submucosal tissue graft constructs|
|US6576265||18 Oct 2000||10 Jun 2003||Acell, Inc.||Tissue regenerative composition, method of making, and method of use thereof|
|US6666892||27 May 1999||23 Dec 2003||Cook Biotech Incorporated||Multi-formed collagenous biomaterial medical device|
|US6835385||6 May 2003||28 Dec 2004||Carol J. Buck||Compositions and methods for softening, thinning and removing hyperkeratotic tissue|
|US6933326||18 Jun 1999||23 Aug 2005||Lifecell Coporation||Particulate acellular tissue matrix|
|US7358284||20 Jan 2005||15 Apr 2008||Lifecell Corporation||Particulate acellular tissue matrix|
|US7425322||24 Sep 2004||16 Sep 2008||Yissum Research Development Company Of The Hebrew University Of Jerusalem||Responsive biomedical composites|
|US7498040||12 Oct 2005||3 Mar 2009||Lifenet Health||Compositions for repair of defects in osseous tissues, and methods of making the same|
|US7498041||12 Oct 2005||3 Mar 2009||Lifenet Health||Composition for repair of defects in osseous tissues|
|US7799767||21 Feb 2003||21 Sep 2010||Pioneer Surgical Orthobiologics, Inc.||Cross-linked bioactive hydrogel matrices|
|US7838021||18 Jun 2004||23 Nov 2010||Universite Paris 5||Platforms, particularly prostheses, having biologically active coverings|
|US8067149||7 Jun 2002||29 Nov 2011||Lifecell Corporation||Acellular dermal matrix and method of use thereof for grafting|
|US8257372 *||29 Dec 2009||4 Sep 2012||Kci Licensing, Inc.||System for providing fluid flow to nerve tissues|
|US8324449||16 Sep 2010||4 Dec 2012||Lifecell Corporation||Acellular tissue matrices made from alpha-1,3-galactose-deficient tissue|
|US9238793||5 Sep 2013||19 Jan 2016||Lifecell Corporation||Method for enzymatic treatment of tissue products|
|US20020103542||18 Sep 2001||1 Aug 2002||Bilbo Patrick R.||Methods for treating a patient using a bioengineered flat sheet graft prostheses|
|US20030035843||7 Jun 2002||20 Feb 2003||Lifecell Corporation, A Delaware Corporation||Method for processing and preserving collagen-based tissues for transplantation|
|US20030143207||18 Oct 2002||31 Jul 2003||Livesey Stephen A.||Remodeling of tissues and organ|
|US20040037735||23 Aug 2002||26 Feb 2004||Depaula Carl Alexander||Allograft tissue purification process for cleaning bone|
|US20040191226||4 Dec 2003||30 Sep 2004||Badylak Stephen F.||Method for repair of body wall|
|US20050028228||21 Jul 2004||3 Feb 2005||Lifecell Corporation||Acellular tissue matrices made from alpa-1,3-galactose-deficient tissue|
|US20050159822||20 Jan 2005||21 Jul 2005||Lifecell Corporation, A Delaware Corporation||Particulate acellular tissue matrix|
|US20060073592||6 Oct 2004||6 Apr 2006||Wendell Sun||Methods of storing tissue matrices|
|US20060127375||18 Jan 2006||15 Jun 2006||Lifecell Corporation||Cryopreservation of human red blood cells|
|US20060159641||27 Feb 2006||20 Jul 2006||Biomedical Design, Inc.||Variably crosslinked tissue|
|US20060210960||7 Jul 2005||21 Sep 2006||Lifecell Corporation, A Texas Corporation||Method for processing and preserving collagen-based tissues for transplantation|
|US20060272102||4 Apr 2003||7 Dec 2006||Novozymes North America, Inc.||Strength and abrasion resistance of durable press finished cellulosic materials|
|US20070009586||7 Jul 2006||11 Jan 2007||Cohen Kelman I||Wound dressings containing complexes of transition metals and alginate for elastase sequestering|
|US20070078522||20 Jan 2005||5 Apr 2007||Lifecell Corporation||Particulate Acellular Tissue Matrix|
|US20070104759||21 Dec 2006||10 May 2007||Qlt Usa, Inc.||Polymeric delivery formulations of leuprolide with improved efficacy|
|US20070248575||19 Apr 2006||25 Oct 2007||Jerome Connor||Bone graft composition|
|US20080027542||9 May 2007||31 Jan 2008||Lifecell Corporation||Reinforced Biological Tissue|
|US20080027562||14 May 2007||31 Jan 2008||Toshiya Fujisato||Method for preparing biological scaffold materials|
|US20090035289||26 Sep 2006||5 Feb 2009||Lifecell Corporation||Dry platelet composition|
|US20090130221||28 Mar 2007||21 May 2009||Fiona Bolland||Decellularisation of tissue matrices for bladder implantation|
|US20090239809||11 Dec 2008||24 Sep 2009||Food Industry Research And Development Institute||Process For Preparing Peptide Products For Promoting Cholecystokinin Secretion And Use Of The Peptide Products|
|US20090306790||4 Jun 2009||10 Dec 2009||Wendell Sun||Elastase Treatment of Tissue Matrices|
|US20100021961||10 Oct 2006||28 Jan 2010||Japan Health Sciences Foundation||Method for preparing biological scaffold material|
|US20100040687||13 Aug 2009||18 Feb 2010||Kci Licensing, Inc.||Tissue Scaffolds|
|US20100209408||3 Mar 2010||19 Aug 2010||Lifecell Corporation||Remodeling of Tissues and Organs|
|US20100233235||17 Feb 2010||16 Sep 2010||Matheny Robert G||Compositions and methods for preventing cardiac arrhythmia|
|US20100272782||9 Jul 2008||28 Oct 2010||Owens Rick T||Acellular tissue matrix compositions for tissue repair|
|US20110020271||20 May 2010||27 Jan 2011||Humacyte, Inc.||Elastin for soft tissue augmentation|
|US20110021753||27 Jul 2009||27 Jan 2011||National Cheng Kung University||Method for Preparing Porous Collagen Matrices|
|US20120010728||7 Jul 2011||12 Jan 2012||Lifecell Corporation||Method for shaping tissue matrices|
|US20120040013||9 Aug 2011||16 Feb 2012||LifeCell Corporation.||Regenerative Tissue Scaffolds|
|US20120252065||3 Apr 2012||4 Oct 2012||Luis Rozenszain||Aqueous process for preparing protein isolate and hydrolyzed protein from an oilseed|
|US20120263763||13 Apr 2012||18 Oct 2012||Lifecell Corporation||Regenerative materials|
|US20120276213||27 Apr 2012||1 Nov 2012||Lifecell Corporation||Method for enzymatic treatment of tissue products|
|US20130013068||4 Jan 2010||10 Jan 2013||James Forsell||Acellular Dermal Allografts And Method Of Preparation|
|US20130053960||14 Sep 2012||28 Feb 2013||Lifecell Corporation||Reinforced biologic material|
|US20130121970||8 Nov 2012||16 May 2013||Lifecell Corporation||Method for elimination of space through tissue approximation|
|US20130158676||18 Dec 2012||20 Jun 2013||Lifecell Corporation||Flowable tissue products|
|US20140004549||5 Sep 2013||2 Jan 2014||Lifecell Corporation||Method for Enzymatic Treatment of Tissue Products|
|US20140377833||5 Sep 2014||25 Dec 2014||Lifecell Corporation||Method for enzymatic treatment of tissue products|
|CN1266716A||12 Mar 1999||20 Sep 2000||中国人民解放军第四军医大学第一附属医院||Cross-linking type acellular pork skin|
|JP2004107303A||Title not available|
|WO2001091671A1||1 Jun 2001||6 Dec 2001||Crosscart, Inc.||Xenograft heart valves|
|WO2002049687A1||14 Dec 2001||27 Jun 2002||Vettivetpillai Ketharanathan||Method of creating biological and biosynthetic material for implantation|
|WO2003017826A2||27 Aug 2002||6 Mar 2003||Regeneration Technologies, Inc.||Processed soft tissue for topical or internal application|
|WO2003032735A1||18 Oct 2002||24 Apr 2003||Lifecell Corporation||Remodeling of tissues and organs|
|WO2004020470A1||28 Feb 2003||11 Mar 2004||Tissue Engineering Initiative Co., Ltd.||Process for producing collagen treated with cysteine protease and collagen treated with cysteine protease|
|WO2005009134A1||21 Jul 2004||3 Feb 2005||Lifecell Corporation||ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE|
|WO2007043513A1||10 Oct 2006||19 Apr 2007||Japan Health Sciences Foundation||Method for production of bio-derived scaffold|
|WO2009009620A2||9 Jul 2008||15 Jan 2009||Lifecell Corporation||Acellular tissue matrix compositions for tissue repair|
|WO2010019753A2||13 Aug 2009||18 Feb 2010||Kci Licensing, Inc.||Tissue scaffolds|
|WO2010078353A2||29 Dec 2009||8 Jul 2010||Kci Licensing, Inc.||Systems for providing fluid flow to tissues|
|WO2012142419A1||13 Apr 2012||18 Oct 2012||Lifecell Corporation||Regenerative materials|
|WO2012166784A1||30 May 2012||6 Dec 2012||Lifecell Corporation||Adipose tissue matrices|
|WO2013016571A1||26 Jul 2012||31 Jan 2013||Harbor Medtech, Inc.||Crosslinked human or animal tissue products and their methods of manufacture and use|
|1||Ahn et al., "The past, present, and future of xenotransplantation" Yonsei Med J., 45(6):1017-1024 (Dec. 31, 2004).|
|2||Allman et al., "Xenogeneic Extracellular Matrix Grafts Elicit a TH2-Restricted Immune Response" Transplantation, 71(11):1631-1640 (Jun. 15, 2001).|
|3||Aycock et al., "Parastomal Hernia Repair With Acellular Dermal Matrix" J. Wound Ostomy Continence Nurs., 34(5):521-523 (2007).|
|4||Badylak et al., "Endothelial cell adherence to small intestinal submucosa: An acellular bioscaffold" Biomaterials, 20:2257-2263 (1999).|
|5||Badylak et al., "Extracellular Matrix As a Biological Scaffold Material: Structure and Function" Acta Biomaterialia, 5(1):1-13 (2009).|
|6||Beniker et al., "The use of acellular dermal matrix as a scaffold for periosteum replacement" Orthopedics, 26(5 Suppl):s591-s596 (May 2003).|
|7||Bruder et al., "The Effect of Implants Loaded with Autologous Mesenchymal Stem Cells on the Healing of Canine Segmental Bone Defects" J. Bone Joint Surg., 80:985-986 (1998).|
|8||Buma et al., "Tissue engineering of the meniscus" Biomaterials, 25(9):1523-1532 (2004).|
|9||Chaplin et al., "Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study" Neurosurgery, 45(2):320-327 (Aug. 1999).|
|10||Chen et al. "Acellular Collagen Matrix As a Possible 'Off the Shelf' Biomaterial for Urethral Repair" Urology, 54(3):407-410 (1999).|
|11||Collins et al., "Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection" J. Immunol., 154:5500-5510 (1995).|
|12||Collins et al., "Cardiac xenografts between primate species provide evidence for the importance of the α-galactosyl determinant in hyperacute rejection" J. Immunol., 154:5500-5510 (1995).|
|13||Costantino et al., "Human Dural Replacement With Acellular Dermis: Clinical Results and a Review of the Literature" Head & Neck, 22:765-771 (Dec. 2000).|
|14||Dobrin et al., "Elastase, collagenase, and the biaxial elastic properties of dog carotid artery" Am. J. Physiol. Heart Circ. Physiol., 247:H124-H131 (1984).|
|15||Edel, "The use of a connective tissue graft for closure over an immediate implant covered with occlusive membrane" Clin. Oral Implants Res., 6:60-65 (1995) (Abstract).|
|16||Fowler et al., "Ridge Preservation Utilizing an Acellular Dermal Allograft and Demineralized Freeze-Dried Bone Allograft: Part II. Immediate Endosseous Impact Placement" J. Periodontol., 71:1360-1364 (2000).|
|17||Fowler et al., "Root Coverage with an Acellular Dermal Allograft: A Three-Month Case Report" J. Contemp. Dental Pract., 1(3):1-8 (2000).|
|18||*||Galie et al., Simultaneous Application of interstitial flow and cyclic mechanical stain to three-dimensional cell seeded hydrogel, Tissue Engineering, Part C, vol. 17, 2011, p. 527-536.|
|19||Galili et al., "Interaction Between Human Natural Anti-alpha-Galactosyl Immunoglobulin G and Bacteria of the Human Flora" Infect. Immun., 56(7):1730-1737 (1988).|
|20||Galili et al., "Interaction Between Human Natural Anti-α-Galactosyl Immunoglobulin G and Bacteria of the Human Flora" Infect. Immun., 56(7):1730-1737 (1988).|
|21||Galili et al., "Interaction of the Natural Anti-Gal Antibody with alpha-Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans" Immunology Today, 14(10):480-482 (1993).|
|22||Galili et al., "Interaction of the Natural Anti-Gal Antibody with α-Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans" Immunology Today, 14(10):480-482 (1993).|
|23||Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of alpha-Galactosyl Epitopes on Nucleated Cells" J. Biol. Chem., 263(33):17755-17762 (1988).|
|24||Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of α-Galactosyl Epitopes on Nucleated Cells" J. Biol. Chem., 263(33):17755-17762 (1988).|
|25||Gamba et al. "Experimental abdominal wall defect repaired with acellular matrix" Pediatr. Surg. Int., 18:327-331 (2002).|
|26||Gebhart et al., "A radiographical and biomechanical study of demineralized bone matrix implanted into a bone defect of rat femurs with and without bone marrow" Acta Orthop. Belg., 57(2):130-143 (1991) (Abstract).|
|27||Greenstein et al., "Parastomal Hernia Repair Using Cross-Linked Porcine Dermis: Report of a Case" Surg. Today, 38:1048-1051 (2008).|
|28||Griffey et al., "Particulate Dermal Matrix as an Injectable Soft Tissue Replacement Material" J. Biomed. Mater. Res. (Appl. Biomater.), 58(1):10-15 (2001).|
|29||Hamadeh et al., "Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces," J. Clin. Invest. 89:1223-1235 (1992).|
|30||Harris, "A Comparative Study of Root Coverage Obtained with an Acellular Dermal Matrix Versus a Connective Tissue Graft: Results of 107 Recession Defects in 50 Consecutively Treated Patients" Int. J. Periodontics Restorative Dentist., 20(1):51-59 (2000).|
|31||Harris, "Root Coverage With a Connective Tissue With Partial Thickness Double Pedicle Graft and an Acellular Dermal Matrix Graft: A Clinical and Histological Evaluation of a Case Report" J. Periodontol., 69:1305-1311 (1998).|
|32||International Search Report and Written Opinion, dated: Jul. 16, 2014, for International Patent Application No. PCT/US2014/012854.|
|33||Ionescu et al., "Effect of Papain and Bromelin on Muscle and Collagen Proteins in Beef Meat," The Annals of the University Dunarea de Jos of Galati. Fascicle VI, Food Technology, New Series, pp. 9-16, 2008.|
|34||Karlinsky et al., "In Vitro Effects of Elastase and Collagenase on Mechanical Properties of Hamster Lungs," Chest, 69 (2):275-276 (1976).|
|35||Kish et al., "Acellular Dermal Matrix (AlloDerm): New Material in the Repair of Stoma Site Hernias" The American Surgeon, 71:1047-1050 (Dec. 2005).|
|36||Kridel et al., "Septal Perforation Repair with Acellular Human Dermal Allograft" Arch. Otolaryngol. Head Neck Surg., 124:73-78 (Jan. 1998).|
|37||Laidlaw et al., "Tympanic Membrane Repair With a Dermal Allograft" Laryngoscope, 111:702-707 (Apr. 2001).|
|38||Lee et al., "In vitro evaluation of a poly(lactide-co-glycolide)-collagen composite scaffold for bone regeneration" Biomaterials, 27:3466-3472 (2006).|
|39||Lu et al., "Novel Porous Aortic Elastin and Collagen Scaffolds for Tissue Engineering" Biomaterials, 25(22):5227-5237 (2004).|
|40||Reihsner et al., "Biomechanical properties of elastase treated palmar aponeuroses," Connective Tissue Research, 26:77-86 (1991).|
|41||Simon et al., "Early failure of the tissue engineered porcine heart valve SYNERGRAFT(TM) in pediatric patients" Eur. J. Cardiothorac. Surg., 23(6)1002-1006 (2003).|
|42||Simon et al., "Early failure of the tissue engineered porcine heart valve SYNERGRAFT™ in pediatric patients" Eur. J. Cardiothorac. Surg., 23(6)1002-1006 (2003).|
|43||Tedder et al., "Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering," Tissue Engineering: Part A, pp. 1-12 (2008).|
|44||Xu, "A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-?-(1,3)-Galactose and Retention of Matrix Structure," Tissue Engineering, vol. 15, 1-13 (2009).|
|45||Yuan et al., "Effects of collagenase and elastase on the mechanical properties of lung tissue strips," J. App. Physiol., 89:3-14 (2000).|
|46||Zheng et al. "Porcine small intestine submucosa (SIS) is not an acellular collagenous matrix and contains porcine DNA: Possible implications in human implantation" J. Biomed. Mater. Res. B: Appl. Biomater., 73(1):61-67 (2005).|
|International Classification||A61K35/12, A61L27/36|
|Cooperative Classification||A61L27/24, A61L27/3687, A61K35/12|
|9 Sep 2015||AS||Assignment|
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MONTEIRO, GARY;WAGNER, CHRISTOPHER T.;RODRIGUEZ, NEIL L.;AND OTHERS;SIGNING DATES FROM 20150327 TO 20150406;REEL/FRAME:036517/0740
|17 Feb 2016||AS||Assignment|
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, MINNESOTA
Free format text: SECURITY INTEREST;ASSIGNORS:KINETIC CONCEPTS, INC.;KCI USA, INC.;ACELITY L.P. INC.;AND OTHERS;REEL/FRAME:037845/0497
Effective date: 20160209
|21 Sep 2016||AS||Assignment|
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE
Free format text: SECOND LIEN SECURITY AGREEMENT;ASSIGNORS:KCI USA, INC.;LIFECELL CORPORATION;KCI LICENSING, INC.;REEL/FRAME:040098/0268
Effective date: 20160920
|7 Oct 2016||AS||Assignment|
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE
Free format text: LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:KCI USA, INC.;LIFECELL CORPORATION;KCI LICENSING, INC.;REEL/FRAME:040291/0237
Effective date: 20161006
|2 Feb 2017||AS||Assignment|
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 040291/0237;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0702
Effective date: 20170131
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 037845/0497;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0603
Effective date: 20170131
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 040098/0268;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0554
Effective date: 20170131